pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immuno-oncology · news · pharmadog
← back to Immuno-oncology
News mentioning Immuno-oncology
47
stories
22h
Vaccine biotech Evaxion halts infectious disease, autoimmune work to focus on oncology
fiercebiotech
6d
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
fiercebiotech
9d
BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’
fiercebiotech
14d
Beyond the needle: The future of intratumoral therapy
biospace
18d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
22d
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
biospace
22d
Astellas buys option on preclinical IL-12 cancer drug from Audax Biosciences
endpoints
23d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
24d
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
biospace
24d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
27d
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
endpoints
27d
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
28d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
28d
Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal
fiercebiotech
29d
ESMO 2026: Merck’s Kelun-partnered ADC hits the ‘Goldilocks zone,’ VP says
biospace
Oct 19, 26
More arms, more questions: The new challenge in multispecific drug design
biospace
Oct 15, 26
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
stat
Oct 15, 26
Webinar: The China question: Can US biotechs lead as investment heads east?
biospace
Oct 13, 26
BioNTech’s mRNA cancer vaccine fails phase 3 test, significantly denting analysts’ confidence
fiercebiotech
Oct 11, 26
The 2026 Biotech Graveyard
fiercebiotech
Oct 9, 26
Parkinson's cell therapy biotech Aspen and I&I startup Bambusa file for IPOs
endpoints
Oct 8, 26
Eli Lilly and the LA Dodgers: A tale of 2 dynasties
biospace
Oct 8, 26
Chutes & Ladders—Vir looks to Liu to lead late-stage push
fiercebiotech
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 14, 26
After a brief storm of political headwinds, mRNA is back with strong momentum
biospace
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 9, 26
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 8, 26
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
fiercebiotech
Sep 3, 26
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
← prev
page 1 of 2
next →